A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

May 23, 2024

Study Completion Date

May 23, 2024

Conditions

Healthy

Interventions

DRUG

RPV LA

RPV LA will be administered at different formulations.

DRUG

CAB LA

CAB LA will be administered at formulation 3.

Trial Locations (3)

PRA Health Sciences, Lenexa

PRA Health Sciences, Salt Lake City

PRA Health Sciences, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT05112939 - A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants | Biotech Hunter | Biotech Hunter